Physician profile
Jared D Knol
NPI 1982867891
$1,439.73
in general payments reported to CMS, 2019-2025
25 companies · $359 in 2025
The $359 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $297 · 2020: $12.45 · 2021: $58.98 · 2022: $214 · 2023: $155 · 2024: $343 · 2025: $359.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $832 · Education: $25.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $831.50 |
| Education | $25.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $156.09 | 2022-2025 | Keytruda, Keytruda Qlex, Welireg |
| E.R. Squibb & Sons, L.L.C. | $149.71 | 2021-2025 | Opdivo |
| Astrazeneca Pharmaceuticals Lp | $113.05 | 2019-2022 | |
| Foundation Medicine, INC. | $112.08 | 2019 | |
| Gilead Sciences, INC. | $109.23 | 2022-2023 | Trodelvy |
| Springworks Therapeutics, INC. | $86.77 | 2024-2025 | Ogsiveo |
| Pharmacyclics LLC, An Abbvie Company | $85.00 | 2022 | |
| Shorla Oncology INC. | $71.20 | 2025 | |
| Novartis Pharmaceuticals Corporation | $60.27 | 2022-2024 | |
| Array Biopharma INC | $59.94 | 2019 | |
| Astellas Pharma US INC | $56.37 | 2024-2025 | Xtandi, Xospata |
| Pfizer INC. | $48.52 | 2024-2025 | |
| Kite Pharma, INC. | $47.15 | 2024-2025 | Yescarta |
| Aadi Bioscience, INC. | $37.78 | 2023 | Fyarro |
| Agios Pharmaceuticals, INC. | $33.70 | 2025 | Pyrukynd |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $26.50 | 2025 | Ojjaara |
| Abbvie INC. | $25.19 | 2024 | |
| Eisai INC. | $24.50 | 2022 | |
| Myovant Sciences INC. | $23.93 | 2021 | |
| Amneal Pharmaceuticals LLC | $22.25 | 2024 | Avastin |
| Daiichi Sankyo INC. | $21.04 | 2024 | Enhertu |
| Amgen INC. | $20.50 | 2019 | |
| Celgene Corporation | $18.86 | 2024 | Reblozyl |
| Jazz Pharmaceuticals INC. | $17.65 | 2019 | |
| Karyopharm Therapeutics INC. | $12.45 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jared Knol listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.